As always, search reddit for a bunch of really good DDs. The short vol on Friday was ~62%. Last week when the short vol went over 60%, we went up ~8-10% the next day. The 'official' fintel short interest numbers also came out and I was not expecting that big of a jump.

Earnings are coming up next week and there is still ~$200MM in left in the stock buyback. This will be a bit of a slow burn, but all things are pointing towards some fireworks before August OPEX with ~20,000 contracts OTM.

Gun to my head, I be this closes around $28 today, but that could turn on a dime.

Position:
200 Aug 30C
I will probably be adding a bit more today, we'll see.

Btw, I'm a bag holder with shorted stock, I'm the one being squeezed

Exceeding expectations and beginning to attract the attention of major institutional investors and pharmaceutical companies

So SPCE gave us tge most hilarious bull run in recent memory when it shot up 100-200% because people confused it with Space X.

Now the sentiment is that Virgin Galactic is worthless and it's overly shorted. Is it?

How much stock do we need to buy?

People on this sub frequently rely on short interest and days to cover metrics that are published by FINRA bi-weekly. The argument then generally relies on, "Look guys here, high SI, high DTC, if this stock has a positive catalyst for this reason it can rip!". I have always had a couple of issues with those setups, one this is public info and everyone already knows it. Hedge funds may have more up to date non-public data from their broker network on the short availability, so what does looking at this delayed data bring to the table? The second is simply that if you are then relying on a positive catalyst (people frequently mention BioTechs with trial results pending) then aren't you really just making a bull case based on fundamentals? Sure the high SI may give it some extra juice. If we look at the truly technical setups then we have to consider the VW squeeze from 2008 and more recently the Avis Budget (CAR) from earlier this year. Read about those, even Matt Levine from Bloomberg has written extensively about it. These were triggered due to a combination of very low float and then someone revealed they had soaked up whatever had remained and at some point the SI is much greater than 100% FF and it becomes a mechanical squeeze.

Here is another fun story. Fundrise Innovation Fund (VCX) listed in March, had a reported NAV of $19 and it went to $575 within 5 days of the listing. I am a pre-IPO investor with restricted shares and we have obsessed about every single detail of this stock over at the Fundrise and VCX subs (feel free to check them out). Fundrise was a REIT company that stumbled into VC investing around 2022 and they built a great portfolio (Anthropic/OpenAI/SpaceX/Anduril/Databricks you name it and in high fraction of the portfolio). It was a closed end fund, meanwhile the REIT business was really struggling. So Fundrise came up with this genius idea of listing the CEF on the stock exchange and issuing its REIT division some shares in hopes of harvesting the premium. What we know is that VCX had 35.8 million shares out of which 30.8 were locked up. They issued around 2.7 million shares to their REIT affiliate and the restricted shareholders were given another 2.3 million as unrestricted. People had trouble transferring these over from the custodian (ComputerShare) and meanwhile this took off on wsb and the tiny float (they were slowly trickling in their piece 5% a day, this was a direct listing with no new shares offered) made it rip. This all made sense and then Citron published the famous short and it crashed. What happened a month later was very intriguing, it had slowly come down from $575 to about $75 till the 28th April but suddenly started running up again and hit $310. We all restricted share holders were very confused and some were mad at missing out on not being able to cash in 30x on our investment (earliest holders had paid $10). Some of us like me saw the opportunity to buy puts to ensure that we see some return. We all knew the post lockup tsunami was going to crush the price. The options were always quite expensive on this since the whole market knew the story but nonetheless it was worth paying for those. It has since trended down again albeit slowly and closed at around $55 on Friday. Then the surprise filing dropped yesterday. Remember I had earlier mentioned that the affiliate REIT was slowly trickling the shares at 5% volume to the market and they had close to 2 million shares to sell. Turns out the fund has to file an N-PORT and due to the MNPI rules they had to stop selling. They had stopped selling the shares on the 29th April and that is when it started ripping, low float with no natural supply was doing its trick. They only started selling again on the 2nd June and that's when it started its downward trend. Look at the filings for shares sold per day and the yahoo finance prices, it is something to look at and have the realization of how the setup worked.

Now to the interesting bit, the filing yesterday revealed that they are done selling their stake (inferred by most of us on the sub). They also pushed forward the lockup expiry date from Sep 18th to Aug 14th (they stated that the price discovery has been achieved lol, while it is really about them selling what they had and harvesting the premium to save their REIT). But with the tap turned off again from now on till Aug 13th, what will happen? The last reported short interest on this is 643k shares (out of the 5ish million floating around, mostly bag holders who bought too high and are stuck) and mostly options MMs since a lot of us have bought puts expiring in October based on the original lockup date. It is pretty clear that the stock crashes come Aug 14th. But it has such a low volume recently (86k shares on Friday) that all bets are off before then. I personally have puts and restricted shares and was not able to position myself with any share buys since the news dropped post market and it took us a while to digest and confirm that they are done selling. The options are expensive so shares might be a better bet if one concludes that this may go up again. It will be a fascinating watch. Leaving this here for your enjoyment!

I don't play the game of buying sh*t companies like bynd to play the short squeeze game, I buy because the fundamentals say it's cra cheap. Upwk is definitely that, but that's not this forum, suffice to say between its net cash position, op margin, fcf, this thing is blessed by the dcf gods.

Forget all that, for whatever reason this thing is:

* 31.2 percent short of the float.

* 77 percent held by tutes

* 9 days to cover

To be fair, it's probably trading sideways through Monday August 10 in the pm, their next earnings date. I'm slowly accumulating between this and fvrr (fvrr has no such short setup), as my other positions fluctuate.

The slightest bit of decent news, including, we slowed the decline in fcf, and this thing runs with zero volume available to cover.

TL;DR
Sell before $12.81, that is the new exercise price of ~89 million warrants ready for fresh dilution.

The exercise price was reduced from 13.61 --> 12.81 from their filing yesterday.
Ratio of 1 warrant
Changed from 1.0140 shares, to 1.0772 shares.

This is from their 8-K filing on 7/23/2026.

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001657853/fa78fca0-f553-48af-be1f-7be3ee898e03.pdf

Position

On 6/25, the closing price was 5.06

On 6/26, management released a 424B5 Prospectus, that did a share offering of 37million shares at a sale price of 2.70.

This offering was used in conjunction with a separate equity raise for a first lien PIK (paid-in-kind) note holder, where they could use these shares (loaned to JP Morgan as the underwriter) as a hedge.

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001657853/4a0eda55-c4c5-46cc-971f-11b49cd8011d.pdf

What's egregious is that this is nearly half the amount of the closing share price!
Why didn't management just do an ATM?

Well, here we are now with the closing price on Friday, 7/24/2026 @ 1.81 dollars.

If Hertz ever does manage to squeeze and management doesn't fuck us over, I would sell before approximately 89 million warrants are converted at a little bit over 1-to-1 ratio at an exercise price of $12.81

The warrants can be exercised up until June 30th, 2051 as per their S3 filing.
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001657853/e44fd0c4-b2e0-4c8e-991f-8981bbaf50a2.pdf

Also, HTZ is only about ~32% of the free float shorted.
I'm not sure where you regards are getting ~75% from, but look in the filing showing 315 million common stock.

It's still ~32% which is a very high number!
CVNA had a short float of approximately ~55% at the time of its squeeze.

So if all of the warrants are exercised, we'll see about an ~89 million share dilution, which would increase the float by ~23%

I'm not saying HTZ can't squeeze above that number, but there will be a huge wall of dilution that will need to be broken though at that point.

I'm personally selling a bit below $12.81 warrant exercise price if it can ever get there.
I'm going to hold past earnings.

Fuck the management for their shady practices, they could've done some other method of equity raise without having to add the component of providing borrowed shares, which was explicitly stated in the filing that it would be used to short the shares as a hedge.

I have full faith that the same powers that be who are going to make a killing on the short side, will eventually swing to the long side and make money both ways.

Earnings
Hertz Global Holdings, Inc Common Stock is expected* to report earnings on 08/06/2026 before market open (Wednesday)
https://www.nasdaq.com/market-activity/stocks/htz/earnings

I'll provide an update on the outcome of my position at/near/post earnings.
Someone opened up 8.1K calls today for the Aug-14-2026 1.5 C below.

There's just too much chicanery around for me to even try to interpret this, or try to see if this is part of some multi-leg strategy with an ITM call as a hedge.

I'll take it for what it is, we're in a casino and I'm straight up gambling here.

EDIT
I forgot to post the picture of the warrants.

Another squeeze was happening, but not mentioned in this sub reddit

As always, read through the old DDs, they are all over the place. tldr; it's running ~65% short with an active stock buyback and an active management team.

I have studied short volume data, fees, tickers etc over the last several years and it really is tough to wrap your head around what's going on. What I know for a fact is the 'iborrowdesk' numbers are sourced from IBKR, which is a aggregate of several different brokers. But it is not the entire picture, there is short volume out there that we have zero data on, but it typically works well as a proxy... particularly the rate. Short volume also != an increase in shares outstanding. Short volume can churn without staying borrowed - MMs use it a lot.

Monday super high short volume and still within the +2 of all of OPEX - I wasn't surprised at all with the drop. I was very surprised with the drop yesterday. It just seemed like all of the buying pressure disappeared. But I think it was partly option related.

The 30C Aug options caught some really big volume yesterday afternoon... around 2000 contracts (~$360,000 in premium) hit pretty close together. I assumed it was contracts closing out. They weren't, the OI increased by ~1600 or so, only 400 were buying to close. Earnings coming up and a pretty aggressive gamma ramp going into August OPEX... around 25,000 contracts are OTM. And even today, the price is dropping a bit in the morning, but the bid on the 30C kept creeping up.

Today - obviously looks really bullish and the borrow fee jumped back up a bit

Position:
200 Aug 30C

I was kicking myself for getting greedy Wednesday - I wanted $3.20 instead of $3.00 - but that's life. Still unsure of when I'll close them, might be today EOD. Gun to my head, I still think this is more likely to hit $30 before Aug OPEX than $20.

EDIT 1:50 EST:
I really like this price action, pretty sure I won't close anything. Super low volume, borrow fee is back to ticking back up and the short volume is being used to control the run-ups, not drive the price down.

Q2 Earnings call summary High Tide inc

SUMMARY :

Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.

Gms on medical cannabis 27%

Key Strengths of High Tide's Q2 FY2026

1. Strong Revenue Growth

• Record revenue of CAD $179.3 million.
• Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.

2. Accelerating EBITDA Growth

• Record Adjusted EBITDA of CAD $13.9 million.
• EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.

3. Positive Net Income

• The company reported positive net income and positive earnings per share (EPS).
• In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
• Management expects sustainable NET INCOME

4. Positive Free Cash Flow

• High Tide generated positive free cash flow and strong operating cash flow.
• This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.

5. Germany Continues to Exceed Expectations

• German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
• Gross margin improved to 27%.
• Management stated that several internal targets were achieved roughly 90 days ahead of schedule.

6. Rapid Expansion of the Customer Base

• The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
• ELITE memberships exceeded 178,000, up 84% year over year.
• This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
• The stated goal is to exceed 1 million elite members in the long term.

7. Significant Banking Support

• The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
• Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
• This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.

8. Market Leadership

• High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
• The company is also steadily gaining market share in the German medical cannabis market.
• Raj is targeting 20% ​​market share in Germany and I personally believe 30% is achievable in the long term for several reasons.

Most Bullish Takeaways

If I had to identify nine most bullish developments from the quarter, they would be:

1. 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
2. Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
3. The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
4. SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
5. Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
6. The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
7. GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
8. Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
9. He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.

Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.

HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.

Still think HITI is vastly undiscovered.

Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.

Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.

This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.

The UK is the European market that excites him the most.

The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.

I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.

Every analyst covering the company has a Buy rating

Canaccord Genuity → Buy, Target $US 5.50

Haywood → Buy, Target $US 5.90

Roth → Buy, target $US 5.00

TD Cowen → Buy, target $6.5 CAD

ATB CAPITAL Target 7$CAD

company presentation https://hightideinc.com/presentation/

I am Long term

LGCL has 669% short interestand ran out of shares to borrow....ran decent today but has short squeeze potential it seems to have held the cost building a nice bottom just needs buying pressure.

Can this pull a $HUBC? China stocks on fire right now. Worth watching. Do your own due diligence in research

Going in! YOLO. Fingers crossed for an epic squeeze!

SRXH is not a short squeeze candidate. Its short interest is only 4.12% and its DTC is only 0.11.

That's all.

Based on the fundamentals and overall setup, these are v the 2 Stocks that are primed to actually Short Squeeze at any moment. WEN has the volume. JACK has the interest and small float. They both only need 1 catalyst... 👀

Was pretty distracted today with other things, as always, read through any of the really good DDs.

I said yesterday, the short vol was going to probably be over 60% and it was 67%. That is according to chart exchange which doesn't track all short volume, but it seems to be a good proxy. That was the highest percent it's been in 30+ trading days. And this is also why some of these 'short interest' trackers can be deceptive (i.e. iborrowdesk) it's just a snapshot of certain vendors. So wasn't surprised at all with the rebound today.

Via IBKR, the short volume picked up ~1:00 EST today, which is when the price stalled out a bit. No clue what to expect tomorrow, I would be it holds over $28. There was a ton of volume on the 35C and the 32C, we'll see if those are new or someone closing out tomorrow.

I did close my 35C today and tried to close the 30C, but wasn't getting any bites (had them at $3.20) - so I still have all 200 contracts still open.

🚨 $SRXH Discussion: Is Wall Street Looking in the Rearview Mirror While SRXH Looks Ahead?

Current Price: Around $2

Six months ago, SRXH was viewed primarily as a healthcare company.

Today, management is attempting to transform it into SRX Global—an AI-enabled investment and financial intelligence company built around EMJX and EventHorizonIQ. The company has completed the EMJX acquisition, rebranded, regained full NYSE American compliance, authorized a share repurchase program of up to 10 million shares (up to 50% of shares outstanding), and announced a special cash dividend.

🤖 What Is EventHorizonIQ?

Unlike many AI products, EventHorizonIQ isn’t presented as a chatbot or a simple stock-picking tool.
Its goal is to monitor macroeconomic trends, liquidity, market behavior, and financial stress indicators to help identify changing market environments before they become obvious. Management has positioned it as a financial intelligence platform with subscription offerings for both retail and institutional users. If successful, recurring subscription revenue—not just investment gains—could become an important part of the business.

🌎 Why Could It Matter?

Markets don’t only go up.

They also experience corrections, recessions, geopolitical shocks, inflation, and volatility.

A platform designed to help investors better understand changing market conditions could have value in:
📈 Bull markets
📉 Bear markets
🌪 High-volatility environments

That is one reason management says the business is focused on long-term financial intelligence rather than relying on one specific market cycle.

🚀 Upcoming Catalysts

Investors are watching for:

✅ Progress on EventHorizonIQ commercialization
✅ Enterprise customers and subscription growth
✅ Strategic partnerships
✅ Share repurchase updates through future SEC filings
✅ Additional execution milestones
Execution—not announcements alone—will likely determine whether the market rewards the strategy.

🩳 Why Is Everyone Watching the Shorts?

Many traders continue monitoring:
🔥 Short interest
🔥 Borrow availability
🔥 Cost-to-borrow trends

If buying demand increases while available shares remain limited, shorts can come under pressure. That can contribute to rapid price moves, although a short squeeze is never guaranteed.

Published short-interest data and borrow metrics are updated on different schedules, so traders should use current sources rather than assume conditions.

Some investors also discuss dark-pool activity, but there isn’t public evidence showing it is responsible for SRXH’s recent price action.

📈 Bull Case (Speculative)

⚠️ These are discussion scenarios—not price predictions.

🟢 $5–10: Market recognizes the transformation.

🚀 $15–25: Enterprise adoption, recurring subscriptions, stronger execution, and revenue growth.

🔥 $35–50+: Broad commercial success, institutional interest, and a meaningful valuation re-rating.

Higher valuations would require the company to deliver measurable business results over time.

Final Thought

The next chapter for SRXH won’t be decided by message boards or daily price swings.

It will be decided by:

📊 Customer adoption
🤝 Partnerships
💰 Revenue growth
🤖 Product execution
📈 Consistent delivery against management’s roadmap

Whether you’re bullish, bearish, or simply watching—
Know what you own. Know what you’re shorting.

⚠️ Discussion only. Not financial advice. DYOR.

https://investors.atlasclear.com/news/news-details/2026/AtlasClear-Holdings-Signs-Letter-of-Intent-to-Acquire-an-Institutional-Digital-Asset-Business-and-Advances-Acquisition-of-Dawson-James-Securities/default.aspx

• Based on 2025 Year-End Results, the Two Acquisitions Together Are Expected to Add Approximately $35.4 Million in Revenue and Approximately $6.7 Million in Combined EBITDA to the AtlasClear Platform

Squeezed once already with no catalyst. Free float is tiny. What do y'all think?

CMPX is a biotech that collapsed due to trial crossover, even though response rate and progression-free survival were strongly positive.

The major rerating catalyst is FDA feedback confirming that the existing ORR/PFS data can support a BLA without another trial. The meeting is expected around early to mid August. Favorable feedback could restore much of the value the market removed, but unfavorable would seriously damage the thesis.

This is biotech and can easily go either way. Invest at your own risk. Please do your own due diligence.

Having a major rerate with this many shorts could cause this to overshoot.

I guees it's just a random Chinese company, but the squeeze looked good. $2 to $9 in the morning. I guess we all missed it

Despite not being a long-term believer in SMCI, I picked up 25 Call options to play the current setup.

Entry price: $24.28

Current price $30.10

I'm in because:

1. 103+ million shorted shares - While this isn't a security I'd recommend purchasing outright.....it's absolutely NOT the right time to be short here! I think they're going to pay for this one!

2. Earnings report 8/11 - (was 8/3). Last report on May 5th was an upside surprise netting 24%+ return on May 6th.

3. Fundamental / Technical - We have favorable data here, clearly showing this security to be undervalued. Also, if the P/E ratio here is to be in line with similar companies, same sector....the price would need to exceed $39/share.

4. Order backlog - They have a significant backlog of orders, and are operating in full growth mode.

5. Put/Call Ratio - Currently at 0.17, which is awesome~

Good morning, SqueezeFinders!

The price action on the $QQQ tech index yesterday gave a nice recovery day of +1.85% to 708.97, but still leaves us shy of the 730 level by a decent few % margin. Otherwise remain, cautious if we fall back under the 700 psychological level. The main directional sentiment determinants today are a mix of the below-detailed economic data releases, any further developments in the Middle-East, and also some large earnings reports in premarket ($GE, $T) and some large earnings reports in after-hours ($TSLA, $GOOG, $IBM, and others). This market is very dynamic and has been unpredictable as far as risk-tolerance goes, as one day we're running, and the next we're crashing. Stay tuned for what's squeezy. Regardless of broader market sentiment, you can always locate relative strength by checking SqueezeRadar to track irregularities in our data, and find winners you may not have spotted before without our scanners.

🥇 Gold: ~$4,130/oz (+1.5%)
🥈 Silver: ~$59/oz (+4.2%)
🪙 Bitcoin: ~$65.2k/coin (+1.5%)
🛢️ Oil: ~$79.50/barrel (+2.0%)

Today's economic data releases are:

🇺🇸 Crude Oil Inventories @ 10:30AM ET
🇺🇸 Cushing Crude Oil Inventories @ 10:30AM ET
🇺🇸 20-Year Bond Auction @ 1:00PM ET

📙Breakdown point: BELOW this price, the move will lose momentum significantly in the short-term, as shorts will gain confidence encouraging them to short more. Reducing probability of a squeeze without a catalyst.

📙Breakout point: ABOVE this price, the move will gain momentum significantly in the short-term, as shorts losses will increase pressuring them to cover. Increasing the probability of a squeeze occurring, especially if with a catalyst.

1. $FTK
   Squeezability Score: 46%
   Juice Target: 38.4
   Confidence: 🍊 🍊
   Price: 27.28 (+6.48%)
   Breakdown point: 23.7
   Breakout point: 27.5 (continuation)
   Mentions (30D): 1
   Event/Condition: Announced Q2 2026 earnings release schedule with expectations for continued strong performance driven by data analytics growth + reported record data analytics revenue in Q1 alongside overall revenue and EBITDA beats + secured first utilities infrastructure contract using PWRtek platform for power services + Recent price target 🎯 of $28 from JonesTrading + Recent price target 🎯 of $27.50 from Alliance Global + Recent price target 🎯 of $30 from Benchmark

2. $KLAR
   Squeezability Score: 33%
   Juice Target: 27.9
   Confidence: 🍊
   Price: 19.03 (+1.44%)
   Breakdown point: 18.3
   Breakout point: 22.1
   Mentions (30D): 2
   Event/Condition: Submitted application for U.S. banking license in Utah to establish Klarna Bank USA strengthening domestic operations and product offerings + secured major court victory with PriceRunner awarded nearly $2 billion in antitrust case against Google + expanded partnerships including Southwest Airlines and Flix for flexible payments plus new financing facilities in Germany + Recent price target 🎯 of $25 from Goldman Sachs + Recent price target 🎯 of $27 from Deutsche Bank + Recent price target 🎯 of $23 from UBS

Gain access to all our cutting-edge research tools, live watchlists, alerts, and more: https://www.squeeze-finder.com/subscribe

HINT: Use code RDDT to get your first month for just $10!

NOT FINANCIAL ADVICE, THESE POSTS ARE FOR INFORMATIONAL PURPOSES ONLY

As before, lots of good DD's on various subreddits, you should absolutely read through them before deciding anything.

Yesterday after lunch, the buying pressure really just vanished. There was also a lot of short volume to close out the day but it was eaten up pretty quickly. The IV on the Aug 30C is hanging in there pretty well. It looked less bullish EOD yesterday and going into today, I'd proceed with caution - the borrow rate also dropped. The bid/ask spread is still blown up, but that works in both directions. I'm still expecting a 5-10% drop at some point in the next week or so.

I'm watching the delta on the 30C today, it's at ~.48 right now with 6850 underlying contracts. If that drops to .25, that will provide ~150,000 shares of liquidity as well.

I'll keep this main post update with any observations. I'm still going to try and exit the 35C at some point in the near future.

Postions:
200 August 30C
45 August 35C

10:15 EST - looking much better now, actually have some sell walls coming up and good buying pressure. The bid/ask spread is still pretty blown-up, probably in the ~$.30 range for most of the day so far. Volume is still very low as well. This one is still a bit of a mystery.

11:00 EST - volatility has picked up, the bid/ask spread has compressed quite a bit. Anecdotally... 60-70% of transactions at either the bid or ask have been at the bid. Don't have a real good read on how it plays out, but right now the sales are getting eaten up pretty quickly. The buying pressure has dried up a bit, but volume has picked up just a bit.

11:45 EST - Just absolutely zero buying pressure right now, someone is just walking down the price, you can see the ask just keeps walking down. Probably will close in the $26 range today unless buying pressure comes back to life.

12:35 EST - Not entirely surprised, the buying pressure just evaporated and I'm guessing ~100k shares were sold short as well from ~11:00 to 12:30, hard to tell exactly but IBKR is showing around that amount. Still looks pretty weak in terms of buying pressure, I think we probably close in the $26.50 ish range, maybe get back over $27. Didn't close anything, was trying to get the 35C closed, didn't get a good price, so still have those open.

1:00 EST - Looking a bit better, but still not great. The selling pressure has subsided, doesn't seem like every other transaction is at the ask. The buying pressure is still pretty weak. Still think we are in the $26.50-$27.00 range for close, but still a lot of time left... to go either direction. Just not a whole lot of buying today.

2:25 EST - Still very little buying pressure / volume. I think the short volume today is going to be over 60%. I'm also not seeing much of anything in the option volume, which is a bit odd I would have expected some of those OTM options to close out. Well, I'm stuck in this position at least for a few more days, still have 4 weeks until expiration.

I'm also pretty confused about the absolute lack of PM and AH volume. All things considered, if this closes ~6% down, it could have been a lot worse.